Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-24
DOI
10.1038/s41419-020-2675-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
- (2019) Qian Zhang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer
- (2018) Weiying Liu et al. INTERNATIONAL JOURNAL OF CANCER
- miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells
- (2018) Xiaomin Meng et al. OncoTargets and Therapy
- Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion
- (2018) Ramona Schulz-Heddergott et al. CANCER CELL
- Regulation of EMT by STAT3 in gastrointestinal cancer (Review)
- (2017) Bo Li et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice
- (2016) Martin Wilhelm et al. Clinical Colorectal Cancer
- Sequestration of Vascular Endothelial Growth Factor (VEGF) Induces Late Restrictive Lung Disease
- (2016) Minna M. Wieck et al. PLoS One
- Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition
- (2015) Hong Liu et al. CARCINOGENESIS
- Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer
- (2015) Yiyao Zhang et al. Oncotarget
- The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: An in vitro study
- (2014) Soha Namazi et al. BIOMEDICINE & PHARMACOTHERAPY
- Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
- (2014) C. Biagi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
- (2014) Matjaz Rokavec et al. JOURNAL OF CLINICAL INVESTIGATION
- Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction
- (2013) Paolo Spallarossa et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10
- (2012) Laurence E. McCahill et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
- (2012) Mélanie Bruchard et al. NATURE MEDICINE
- STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells
- (2011) L. Lin et al. CANCER RESEARCH
- Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up
- (2010) Peter Georgakopoulos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
- (2010) Y Nakai et al. BRITISH JOURNAL OF CANCER
- 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes
- (2010) Barbara Pardini et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- STAT3 Implicated in the Development of Colon Cancer: A Step Closer for Targeted Therapy?
- (2010) George K.K. Lau et al. GASTROENTEROLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity
- (2010) Jian Yang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
- (2009) Heehyoung Lee et al. CANCER CELL
- The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer
- (2009) V. Fendrich et al. GUT
- Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
- (2009) Stefan Wilop et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis
- (2008) Per Albertsson et al. ACTA ONCOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started